Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Sobered Up Using LSD: Journal… >
Sobered Up Using LSD: Journal of Psychopharmacology Article Examines Intriguing Evidence on the Psychedelic Drug

Published: March 8, 2012.
By Norwegian University of Science and Technology
http://www.ntnu.edu

Forty years ago, LSD was used in the treatment of alcoholics - with good results. Perhaps it's time to look at it again?

In the 1950s, '60s and '70s, researchers in many places in the world experimented with LSD in the treatment of various disorders, including alcoholism. Not all experiments were scientifically tenable by today's standards, but some were. Now Teri Krebs and Pål-Ørjan Johansen, researchers at the Norwegian University of Science and Technology (NTNU), have taken a closer look at these experiments.

The results of all of these studies pointed in the same direction, which Krebs and Johansen say is quite clear: A single dose of LSD, provided for treatment purposes, helped heavy alcoholics and made it less likely that they would relapse.

"There has long been a need for better treatments for addiction. We think it is time to look at the use of psychedelics in treating various conditions," the researchers say.

536 alcoholics

The Norwegian researchers found six different studies of LSD and alcoholism that were scientifically sound, in which patients were randomly assigned, as if by tossing a coin, to receive either LSD or a comparison treatment. They combined all the data from these studies, involving a total of 536 people – the first such rigorous quantitative analysis in the world.

All of the studies were conducted either in the U.S. or Canada between 1966 and 1970. The studies all involved individuals who were admitted to treatment for alcoholism and who voluntarily participated in the trials. Nearly all were men.

Within each of the studies all patients were given the same treatment programme. But on one treatment day some patients were given a single large dose of LSD, while control patients received a low dose of LSD or a stimulant drug - or nothing. In some studies, during the duration of the drug effects, patients talked with a therapist, while in other studies, patients received only brief reassurance if they wanted. But all were encouraged to reflect on their alcohol problem.

Neither patients nor the individuals who were treating them knew in advance who would get a full dose of LSD.

Clear improvements - greater opportunities

"In independent and standardized follow-up examinations, ranging from one to twelve months later, all of the studies showed that the patients who had received a full dose of LSD fared the best. On average, 59 per cent of full-dose patients showed a clear improvement compared with 38 per cent in the other groups," say Krebs and Johansen.

LSD patients were less likely to relapse into problematic alcohol use and had higher levels of total abstinence. In some studies their relatives also reported the same findings. Many of the patients said they had gained a new appreciation for their alcohol problem and new motivation to address it.

These patients also reported greater self-acceptance and openness, as well as greater faith in their ability to deal with future problems.

Affects the brain

"We do not yet fully know why LSD works this way," the researchers admit. "But we know that the substance is non-toxic and that it is not addictive. We also know that it has a striking effect on the imagination, perception and memories."

The researchers explain that LSD interacts with a specific type of serotonin receptor in the brain.

"LSD may stimulate the formation of new connections and patterns, and generally seems to open an individual to an awareness of new perspectives and opportunities for action," they say.

Not followed up

By 1971 LSD had been banned for non-medical use, and although the drug was and is still permitted as an experimental medical treatment, it became increasingly difficult to conduct clinical trials. Despite the promising studies, LSD was claimed to have no demonstrated medical use. There may be several reasons for this, the researchers explained.

"The earliest studies reported promising results but also had methodological problems. Many scientists expected unrealistically good results from a single dose, and tended to ignore effects that lasted less than a year. Importantly, many of the individual studies did not have enough patients to reach a conclusion by themselves."

"But when we combine studies that had sound methodology, the results are unambiguous. We can therefore safely conclude that a single dose of LSD had a positive treatment effect that lasted at least six months," Krebs and Johansen said.

Should offer repeated doses

The improvement was greatest during the first few months of treatment. As the months passed, the effect gradually decreased.

"It is unusual for psychiatric drugs to have an effect that lasts for several months after a single dose. We now better understand that alcoholism is a chronic, relapsing disorder that typically requires ongoing treatment. The next step should be to periodically provide additional doses of LSD in combination with modern evidence-based treatment programs," the researchers conclude.

The meta-analysis is being published in the Journal of Psychopharmacology.




Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Dose 
11/18/14 
Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma
By Mayo Clinic
ROCHESTER, Minn. -- The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of …
Pomalidomide 
1/24/13 
New Drug Improves Survival in Multiple Myeloma Relapse, Moffitt Cancer Center Researchers Say
By H. Lee Moffitt Cancer Center & Research Institute
Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after …
Patients 
4/18/12 
Autologous Bone Marrow-derived Mononuclear Cell Transplants Can Reduce Diabetic Amputations
By Cell Transplantation Center of Excellence for Aging and Brain Repair
Autologous (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have been found to significantly induce vascular growth when transplanted into patients with diabetes who are suffering from critical limb …
Citalopram 
2/19/14 
JAMA Study Shows Medication to Treat Agitation for Alzheimer Disease Shows Mixed Results
By University of Rochester Medical Center
The results of a Journal of the American Medical Association study offer a glimmer of hope to families caring for a loved one with Alzheimer's disease. Researchers at the …
Patients 
2/1/12 
Experimental Drug Reduces 'Second Stroke' After Aneurysm Rupture
By American Heart Association
An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research presented at the American Stroke Association's International Stroke Conference …
Avm 
3/26/13 
Radiosurgery for Treating Unruptured Intracranial Arteriovenous Malformations
By Journal of Neurosurgery Publishing Group
Charlottesville, VA (March 26, 2013). Researchers at the University of Virginia (UVA) Health System recommend radiosurgery for treating unruptured arteriovenous malformations (AVMs), because the procedure has a reasonable benefit-to-risk …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition